Skip to main content

FDA commissioner praises Eli Lilly Alzheimer's treatment results

Donanemab slowed the decline in memory, in thinking and in the ability to conduct daily activities by 35%, according to Lilly's data.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.